請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24231完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李銘仁(Ming-Jen Lee) | |
| dc.contributor.author | Yung-Cheng Chen | en |
| dc.contributor.author | 陳永崢 | zh_TW |
| dc.date.accessioned | 2021-06-08T05:19:10Z | - |
| dc.date.copyright | 2011-10-05 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2011-07-29 | |
| dc.identifier.citation | 1.Abelmann WH, Lorell BH (1989). The challenge of cardiomyopathy. J Am Coll Cardiol 13(6): 1219-1239.
2.Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG (2005). Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 352(4): 362-372. 3.Arad M, Penas-Lado M, Monserrat L, Maron BJ, Sherrid M, Ho CY, Barr S, Karim A, Olson TM, Kamisago M, Seidman JG, Seidman CE (2005). Gene mutations in apical hypertrophic cardiomyopathy. Circulation 112(18): 2805-2811. 4.Bos JM, Poley RN, Ny M, Tester DJ, Xu X, Vatta M, Towbin JA, Gersh BJ, Ommen SR, Ackerman MJ (2006). Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab. 88(1): 78-85. 5.Carrier L (2007). Cardiac myosin-binding protein C in the heart. Arch Mal Coeur Vaiss 100(3): 238-243. 6.Chang AN, Potter JD (2005). Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail Rev 10(3): 225-235. 7.Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC, Isnard R, Hagege A, Langlard JM, Bonne G, Richard P, Hainque B, Bouhour JB, Schwartz K, Komajda M (1998). Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene Circulation 97(22): 2230-2236. 8.Corrado D, Thiene G (2006). Arrhythmogenic right ventricular cardiomyopathy/dysplasia: Clinical impact of molecular genetic studies. Circulation 113(13): 1634-1637. 9.Dec GW, Fuster V (1994). Idiopathic dilated cardiomyopathy. N Engl J Med 331(23): 1564-1575. 10.Devereux RB, Roman MJ, Paranicas M, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Rodeheffer RJ, Cowan LD, Howard BV (2001). A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. Am Heart J 141(3): 439-446. 11.Ehlermann P, Weichenhan D, Zehelein J, Steen H, Pribe R, Zeller R, Lehrke S, Zugck C, Ivandic BT, Katus HA (2008). Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med Genet. 9: 95. 12.Erdmann J, Raible J, Maki-Abadi J, Hummel M, Hammann J, Wollnik B, Frantz E, Fleck E, Hetzer R, Regitz-Zagrosek V (2001). Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 38(2): 322-330. 13.Disease-causing mutations in the human cardiac Myosin-Binding Protein C gene. Genomics of Cardiovascular Development, Adaptation, and Remodeling. NHLBI Program for Genomic Applications, Harvard Medical School.(Jun.2011 accessed) URL: http://www.cardiogenomics.org 14.Gilbert R, Kelly MG, Mikawa T, Fischman DA (1996). The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J Cell Sci 109 ( Pt 1): 101-111. 15.Hatle, LK, Appleton, CP, Popp, RL(1989). Differentiation of constrictive pericarditis and restrictive cardiomyopathy by Doppler echocardiography. Circulation 79(2): 357-370. 16.Hershberger RE, Cowan J, Morales A, Siegfried JD (2009). Progress with genetic cardiomyopathies: Screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2(3): 253-261. 17.Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG, Seidman CE (2000). Homozygous mutation in cardiac troponin T: Implications for hypertrophic cardiomyopathy. Circulation 102(16): 1950-1955. 18.James SK, Lindback J, Tilly J, Siegbahn A, Venge P, Armstrong P, Califf R, Simoons ML, Wallentin L, Lindahl B (2006). Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality Benefit From Coronary Revascularization in Acute Coronary Syndromes: A GUSTO-IV Substudy. J Am Coll Cardiol 48(6): 1146-1154. 19.Kantharia BK, Richards HB, Battaglia J (1995). Reversible dilated cardiomyopathy: an unusual case of thyrotoxicosis. Am Heart J 129(5): 1030-1032. 20.Khouri SJ, Maly GT, Suh DD, Walsh TE (2004). A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 17(3): 290-297. 21.Kimura A (2008). Molecular etiology and pathogenesis of hereditary cardiomyopathy. Circ J 72(Suppl A): A38-48. 22.Konno T, Shimizu M, Ino H, Matsuyama T, Yamaguchi M, Terai H, Hayashi K, Mabuchi T, Kiyama M, Sakata K, Hayashi T, Inoue M, Kaneda T, Mabuchi H (2003). A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients. J Am Coll Cardiol 41(5): 781-786. 23.Ko YL,Chen JJ, Tang TK, Teng MS, Lin SY, Kuan P, Wu CW, Lien WP, Liew CC (1996). Mapping the locus for familial hypertrophic cardiomyopathy to chromosome 11 in a family with a case of apical hypertrophic cardiomyopathy of the Japanese type.Hum Genet. 97(4):457-61. 24.Ko YL, Lei MH, Chiang FT, Chen JJ, Kuan P, Lien WP (1992). Apical hypertrophic cardiomyopathy of the Japanese type: occurrence with familial hypertrophic cardiomyopathy in a family. Am Heart J. 124(6):1626-1630. 25.Ko YL, Tang TK, Chen JJ, Hshieh YY, Wu CW, Lien WP (1992). Idiopathic hypertrophic cardiomyopathy in identical twins. Morphological heterogeneity of the left ventricle. Chest 102(3): 783-785. 26.Ko YL, Teng MS, Tang TK, Chen JJ, Lee YS, Wu CW, Lien WP, Liew CC (1998) Genetic heterogeneity for familial hypertrophic cardiomyopathy in Chinese: analysis of six Chinese kindreds. Chin Med J (Engl).111(5):416-421. 27.Kushwaha SS, Fallon JT, Fuster V(1997). Restrictive cardiomyopathy. N Engl J Med 336(4): 267-276. 28.Li M, Cheng K, Wang QB, Zhu WQ, Qin SM, Cui J, Shu XH, Chen RZ, Ge JB, Chen HZ (2009). Link between cardiac myosin binding protein-C gene mutation of Pro1208fs and Gly507 Arg and hypertrophic cardiomyopathy in Chinese patients. Zhonghua Xin Xue Guan Bing Za Zhi. 37(9):790-793. 29.Lin J, Zheng DD, Tao Q, Yang JH, Jiang WP, Yang XJ, Song JP, Jiang TB, Li X (2010). Two novel mutations of the MYBPC3 gene identified in Chinese families with hypertrophic cardiomyopathy.Can J Cardiol. 26(10): 518-522. 30.Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ (2001). Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103(6): 789-791. 31.Liu WL, Xie WL, Hu DY, Zhu TG, Li YT, Sun YH, Li CL, Li L, Li TC, Bian H, Tong QG, Yang SN, Fan RY, Cui W (2006). Analysis of MYH7, MYBPC3 and TNNT2 gene mutations in 10 Chinese pedigrees with familial hypertrophic cardiomyopathy and the correlation between genotype and phenotype. Zhonghua Xin Xue Guan Bing Za Zhi. 34(3): 202-207. 32.Liviu C, Poliac, Michael E, Barron, Barry J, Maron (2006) Hypertrophic cardiomyopathy. Anesthesiology 104:183-192. 33.Maron BJ (2002). Hypertrophic cardiomyopathy: A systematic review. JAMA 287(10): 1308-1320. 34.Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92(4): 785-789. 35.Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, Udelson JE, Manning WJ (2007). Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol 100(8): 1293-1298. 36.Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003). Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348(4): 295-303. 37.Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, Camici PG (2009). The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 54(9): 866-875. 38.Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology (2003). American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J Am Coll Cardiol 42(9): 1687-1713. 39.Maron BJ, Seidman CE, Ackerman MJ, Towbin JA, Maron MS, Ommen SR, Nishimura RA, Gersh BJ (2009). How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. Circ Cardiovasc Genet 2(1): 81-85. 40.Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C, Watkins H (2009). Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 105(3): 219-222. 41.Ma ZF, Liu WL, Hu DY, Xie WL, Zhu TG, Sun YH, Yang SN, Li CL, Li L, Nie XY, Yang JG, Li TC, Bian H, Tong QG, Xiao J, Wang GH, Cui W, Fan RY, Li YT (2009). Novel MYBPC3 mutations in Chinese patients with hypertrophic cardiomyopath. Zhonghua Xin Xue Guan Bing Za Zhi. 37(8): 734-738. 42.McConnell BK, Jones KA, Fatkin D, Arroyo LH, Lee RT, Aristizabal O, Turnbull DH, Georgakopoulos D, Kass D, Bond M, Niimura H, Schoen FJ, Conner D, Fischman DA, Seidman CE, Seidman JG (1999).Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 104(9): 1235-1244. 43.Mogensen J, Murphy RT, Kubo T, Bahl A, Moon JC, Klausen IC, Elliott PM, McKenna WJ (2004). Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol 44(12): 2315-2325. 44.Montgomery JV, Harris KM, Casey SA, Zenovich AG, Maron BJ (2005). Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. Am J Cardiol 96(2): 270-275. 45.Morita H, DePalma SR, Arad M, McDonough B, Barr S, Duffy C, Maron BJ, Seidman CE, Seidman JG (2002). Molecular epidemiology of hypertrophic cardiomyopathy. Cold Spring Harb Symp Quant Biol 67: 383-388. 46.Morimoto S (2008). Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res 77(4): 659-666. 47.Morita H, Seidman J, Seidman CE (2005). Genetic causes of human heart failure. J Clin Invest 115(3): 518-526. 48.Nia AM, Gassanov N, Dahlem KM, Caglayan E, Hellmich M, Erdmann E, Er F (2011). Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: a pilot study. Clin Res Cardiol 2011 May 3. [Epub ahead of print] 49.Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE (1998). Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 338(18): 1248-1257. 50.Nishi H, Kimura A, Harada H, Adachi K, Koga Y, Sasazuki T, Toshima H (1994). Possible gene dose effect of a mutant cardiac beta-myosin heavy chain gene on the clinical expression of familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 200(1): 549-556. 51.Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, Conte MR, Casazza F, Galderisi M, Maron BJ, Cecchi F (2006). Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 98(7): 960-965. 52.Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ (2005). Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3): 480-487. 53.Ommen SR, Maron BJ, Olivotto I, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA (2005). Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3): 470-476. 54.Palka P, Lange A, Donnelly JE, Nihoyannopoulos P (2000). Differentiation between restrictive cardiomyopathy and constrictive pericarditis by early diastolic doppler myocardial velocity gradient at the posterior wall. Circulation 102(6): 655-662. 55.Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ (2001). Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104(3): 317-324. 56.Poliac LC, Barron ME, Maron BJ (2006). Hypertrophic cardiomyopathy. Anesthesiology 104(1)：183-192. 57.Primo J, Geelen P, Brugada J, Filho AL, Mont L, Wellens F, Valentino M, Brugada P.(1998). Hypertrophic Cardiomyopathy: Role of the Implantable Cardioverter-Defibrillator. J Am Coll Cardiol 31(5): 1081-1085. 58.Rawlins J, Carre F, Kervio G, Papadakis M, Chandra N, Edwards C, Whyte GP, Sharma S (2010). Ethnic differences in physiological cardiac adaptation to intense physical exercise in highly trained female athletes. Circulation 121(9): 1078-1085. 59.Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies (1980) Br Heart J 44:672-673. 60.Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M; EUROGENE Heart Failure Project (2003). Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107(17): 2227-2232. 61.Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P(1996). Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 93(5): 841-842. 62.Roberts R, Sigwart U (2001). New concepts in hypertrophic cardiomyopathies, part I. Circulation 104(17): 2113-2116. 63.Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK, Reiken S, Mende U, Marks AR, Kass DA, Seidman CE, Seidman JG (2002). The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 109(8): 1013-1020. 64.Takahashi-Yanaga F, Morimoto S, Harada K, Minakami R, Shiraishi F, Ohta M, Lu QW, Sasaguri T, Ohtsuki I (2001). Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy. J Mol Cell Cardio 33(12): 2095-2107. 65.van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Winegrad S, Schlossarek S, Carrier L, ten Cate FJ, Stienen GJ, van der Velden J (2009). Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: Haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119(11): 1473-1483. 66.Wang H, Song L, Zou YB, Wang JZ, Sun K, Gao S, Zhang CN, Hui RT (2009).A novel hot-spot mutation S236G in the cardiac myosin binding protein C gene in Chinese patient with hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi. 37(12): 1078-1080. 67.Wang H, Zou YB, Wang JZ, Song L, Sun K, Song XD, Wang XJ, Zhang CN, Hui RT (2008). The genotype-phenotype correlation of MYH7 gene G15391A mutation and MYBPC3 gene G12101A mutation in familial hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi. 36(12):1059-1062. 68.Wang SX, Zou YB, Fu CY, Wang H, Wang JZ, Song XD, Chen JZ, Hui RT (2007). Clinical features of dilated cardiomyopathy-like hypertrophic cardiomyopathy caused by a 13261 G > A mutation in cardiac myosin-binding protein C gene. Zhonghua Xin Xue Guan Bing Za Zhi. 35(1):17-20. 69.Xie WL, Liu WL, Hu DY, Cui W, Zhu TG, Li CL, Sun YH, Li L, Bian H (2005). A frame shift mutation, Arg346fs mutation, is identified in cardiac myosin-binding protein C gene in a Chinese family with hypertrophic cardiomyopathy.Zhonghua Yi Xue Za Zhi. 85(14):963-966. 70.Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J (1998). A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest. 102(7): 1292-1300. 71.Zou YB, Wang JZ, Wu GR, Song L, Wang SX, Yu H, Zhang Q, Wang H, Hui RT (2006). Familiar hypertrophic cardiomyopathy caused by a IVS15-1G > A mutation in cardiac myosin-binding protein C gene. Zhonghua Xin Xue Guan Bing Za Zhi. 34(8): 699-702. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24231 | - |
| dc.description.abstract | 家族性心肌肥厚症是一個具高度外顯率之體染色體顯性遺傳疾病，其臨床表徵差異性大，病人可能毫無症狀或突然發生猝死，目前已發現在肌小節上約11個基因與心肌肥厚症有關，突變型態多達上百種，其中肌凝結合蛋白C（Myosin binding protein C，MYBPC3）是常見的突變點位之一，因此本研究的目的為找出兩個家族性心肌肥厚症之MYBPC3之相關基因型與表現型之間的關連性。本研究針對兩個具有家族性心肌肥厚症之家族之MYBPC3基因所有34個外顯子及外顯子與內顯子連接處，進行基因檢測，實驗結果發現目前為止皆未有文獻紀載的兩種新發生之突變型態，第一種突變發現於Family 1，突變點位於MYBPC3 Exon 31第3624個核苷酸上產生單一鹼基缺失，此基因突變造成codon 1236提早形成終止密碼（Premature stop codon），造成Frameshift mutation，共兩位罹病之家族成員於同樣的基因點位發生突變，其他檢測結果為正常者則無相關臨床表徵；另一型式之突變發生於MYBPC3 Exon 32，第3697個核苷酸產生C>T之突變，由於DNA產生突變，使蛋白質由麩醯胺（Glutamine） 突變為終止密碼（Stop codon），屬Nonsense mutation，而所有具MYBPC3突變之病人其心臟超音波檢查結果皆為異常。綜合以上結果，本研究找到兩種在肌小節之肌凝結合蛋白上產生的新基因突變型，一種為Frameshift mutation，另一種為Nonsense mutation，其指標個案皆有典型之心肌肥厚，伴有缺血性中風之併發症，與先前文獻所證實之Sarcomere基因型突變與家族性心肌肥厚症之表現型有高度關聯性。 | zh_TW |
| dc.description.abstract | Familial Hypertrophic Cardiomyopathy (Familial HCM) is a genetic disease with an autosomal dominant pattern of inheritance. Penetrance for cardiomyopathy is extremely high. However, the clinical manifestations are diverse even in the same family. Familial HCM can be caused by mutations in a number of genes. Hundreds of mutations in 11 responsible genes encoding sarcomeric contractile proteins have been identified. Previous studies found that sarcomeric protein plays an important role in Familial HCM. Mutations in the myosin binding protein C (MYBPC3) are a common cause of Familial HCM. The current study was to investigate the correlation of phenotype and genotype in two kindred of Taiwanese Familial HCM patients. Two Taiwanese HCM families were recruited for mutations screening. The 34 consecutive exons and their exon-intron junctions were sequenced. Two novel sequence variant mutations of MYBPC3 were identified. In Family 1, two subjects with mutation c.3624 delC. in exon 31 was identified, which cause a premature stop codon at codon 1236. In Family 2, a nonsense mutation at c.3697 C>T, leads to p.Glu1233Stop was identified at exon 32 of MYBPC3 gene. The affected family members and probands received echocardiography with the result of HCM. In conclusion, two novel mutations, one for framshift and the other for nonsense in MYBPC3 gene were identified in two executive non-related Taiwanese HCM families. The index cases developed the typical hypertrophic cardiomyopathy with an ischemic stroke. The results are in line with the previous findings that sarcomeric gene mutations are responsible for Familial HCM. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T05:19:10Z (GMT). No. of bitstreams: 1 ntu-100-P98448011-1.pdf: 2706618 bytes, checksum: cf51911ca96a72810dd1ddb26b26ac53 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | 中文摘要…………………………………………………………………I
英文摘要………………………………………………………………II 目 錄……………………………………………………………………III 表目錄 …………………………………………………………………VII 圖目錄 ………………………………………………………………VIII 英文縮寫…………………………………………………………………X 第一章 導論 1.1心肌病變疾病簡介…………………………………………………1 1.1.1心肌病變疾病分類…………………………………………………1 1.1.2病理與解剖生理分類-HCM…………………………………………2 1.1.3病理與解剖生理分類-DCM…………………………………………3 1.1.4 限制型心肌病變…………………………………………………4 1.1.5心律失常性右心室心肌病變………………………………………4 1.1.6 其他原因導致之心肌病變………………………………………5 1.6.1.1 其他基因疾病…………………………………………………5 1.6.1.2其他感染性疾病引起之心肌病變………………………………5 1.6.1.3 Stress-induced cardiomyopathy……………………………6 1.6.1.4 Athlete's heart………………………………………………6 1.6.1.5藥物引起之心肌病變……………………………………………6 1.6.1.6沉積性疾病………………………………………………………7 1.6.1.7電解質異常、營養失調或有毒物質引起心肌病變……………7 1.6.1.8內分泌異常疾病引起之心肌病變……………………………7 1.2 肌肉生理結構與病理機轉…………………………………………8 1.2.1病理生理機轉-左心室出口阻塞…………………………………8 1.2.2病理生理機轉-微血管阻塞………………………………………8 1.2.3病理生理機轉-舒張功能障礙……………………………………9 1.3臨床表現與症狀………………………………………………………9 1.3.1收縮功能障礙及舒張功能障礙……………………………………9 1.3.2心肌病變常見症狀………………………………………………10 1.4疾病診斷與檢查……………………………………………………11 1.4.1理學檢查…………………………………………………………11 1.4.2心臟超音波………………………………………………………11 1.4.3心電圖……………………………………………………………12 1.4.4其他非侵入性影像檢查…………………………………………12 1.4.5血清學檢查………………………………………………………13 1.4.6心導管檢查與切片………………………………………………14 1.5疾病治療及預後……………………………………………………14 1.5.1藥物………………………………………………………………14 1.5.2侵襲性治療………………………………………………………15 1.5.2.1心臟去顫器……………………………………………………15 1.5.2.2心導管電氣燒灼術及酒精心肌栓塞術………………………15 1.5.2.3外科手術………………………………………………………16 1.5.3預後………………………………………………………………16 1.6分子遺傳學研究……………………………………………………17 1.6.1 Thick-Filament Protein之基因突變…………………………18 1.6.1.1 Myosin binding protein C ………………………………18 1.6.1.2 Beta-cardiac myosin heavy chain………………………19 1.6.1.3 Titin…………………………………………………………20 1.6.1.4 Myosin light chain/Essential myosin light chain…20 1.6.2 Thin-Filament Protein之基因突變…………………………21 1.6.2.1 Cardiac troponin T…………………………………………21 1.6.2.2 Cardiac troponin I…………………………………………21 1.6.2.3 Actin…………………………………………………………22 1.6.2.4 Alpha-tropomyosin…………………………………………22 1.6.2.5其他基因突變導致之心肌病變………………………………22 1.7研究目的……………………………………………………………23 第二章 研究材料與實驗方法…………………………………………24 2.1研究對象……………………………………………………………24 2.2研究方法及步驟……………………………………………………24 2.2.1DNA的萃取與定量…………………………………………………24 2.2.2聚合酶連鎖反應…………………………………………………25 2.2.2.1 PCR原理………………………………………………………25 2.2.2.2 PCR反應儀器進行聚合酶連鎖反應…………………………25 2.2.2.3 DNA電泳分析…………………………………………………25 2.2.2.4定序……………………………………………………………26 第三章 結果……………………………………………………………27 3.1檢查結果與臨床表徵………………………………………………27 3.2 MYBPC3 DNA定序結果………………………………………………30 第四章 討論……………………………………………………………31 參考文獻…………………………………………………………………34 | |
| dc.language.iso | zh-TW | |
| dc.subject | 心肌病變 | zh_TW |
| dc.subject | 表現型 | zh_TW |
| dc.subject | 基因突變 | zh_TW |
| dc.subject | 基因型 | zh_TW |
| dc.subject | 肌凝結合蛋白 | zh_TW |
| dc.subject | MYBPC3 | en |
| dc.subject | Mutation | en |
| dc.subject | Phenotype | en |
| dc.subject | Genotype | en |
| dc.subject | Cardiomyopathy | en |
| dc.title | 家族性心肌病變之突變基因分析 | zh_TW |
| dc.title | Molecular Analysis for the Familial Hypertrophic Cardiomyopathy | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 99-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 朱樹勳(Shu-Hsun Chu),余家利(Chia-Li Yu) | |
| dc.subject.keyword | 心肌病變,基因型,表現型,基因突變,肌凝結合蛋白, | zh_TW |
| dc.subject.keyword | Cardiomyopathy,Genotype,Phenotype,Mutation,MYBPC3, | en |
| dc.relation.page | 78 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2011-07-29 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 未授權公開取用 | 2.64 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。